Tier 2 — strong

Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption

T Walle, Y Otake, U K Walle, F A Wilson
The Journal of nutrition 2000 130(11):2658

Bibliography

PubMed
PMID 11053503
DOI
10.1093/jn/130.11.2658
Funding
Indexed grant support: GM55561 — NIGMS NIH HHS — United States; RR01070 — NCRR NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman ileostomy absorption and hydrolysis experiment
ModelHuman intervention research
Sample4 patients with ileostomies
InterventionOnion meal providing quercetin mono- and diglucosides
DurationAcute meal with intestinal effluent analysis
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2000, this source examined forms, absorption and food sources. Design: Human ileostomy absorption and hydrolysis experiment. Sample/model: 4 patients with ileostomies. The exposure or intervention was Onion meal providing quercetin mono- and diglucosides. Follow-up or treatment period: Acute meal with intestinal effluent analysis.

Intact glucosides were not detected in effluent; recovered aglycone supported extensive intestinal hydrolysis before absorption.

Very small mechanistic study using a specific intestinal model. Estimated intestinal disappearance is not systemic bioavailability or clinical efficacy.

Continue with Quercetin Data Center

For topic-level interpretation, read Foods High in Quercetin: Practical Sources and Portions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Intact glucosides were not detected in effluent; recovered aglycone supported extensive intestinal hydrolysis before absorption.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Onion meal providing quercetin mono- and diglucosides; Acute meal with intestinal effluent analysis.

What this study can and cannot tell us

  • Very small mechanistic study using a specific intestinal model. Estimated intestinal disappearance is not systemic bioavailability or clinical efficacy.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology